Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard J. Budhu is active.

Publication


Featured researches published by Richard J. Budhu.


Bioorganic & Medicinal Chemistry Letters | 2001

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure–activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes

Conrad P. Dorn; Paul E. Finke; Bryan Oates; Richard J. Budhu; Sander G. Mills; Malcolm Maccoss; Lorraine Malkowitz; Martin S. Springer; Bruce L. Daugherty; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Anthony Carella; Gwen Carver; Karen Holmes; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; William A. Schleif; Emilio A. Emini

Screening of the Merck sample collection for compounds with CCR5 receptor binding afforded (2S)-2-(3,4-dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2,3-dihydrobenzthiophene-3,4-piperidin-1-yl)]butane S-oxide (4) as a potent lead structure having an IC50 binding affinity of 35 nM. Herein, we describe the discovery of this lead structure and our initial structure activity relationship studies directed toward the requirement for and optimization of the 1-amino fragment.


Bioorganic & Medicinal Chemistry Letters | 2001

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

Jeffrey J. Hale; Richard J. Budhu; Edward Holson; Paul E. Finke; Bryan Oates; Sander G. Mills; Malcolm Maccoss; Sandra L. Gould; Julie A. DeMartino; Martin S. Springer; Salvatore J. Siciliano; Lorraine Malkowitz; William A. Schleif; Daria J. Hazuda; Michael D. Miller; Joseph Kessler; Renee Danzeisen; Karen Holmes; Janet Lineberger; Anthony Carella; Gwen Carver; Emilio A. Emini

Investigations of the structure-activity relationships of 1,3,4-trisubstituted pyrrolidine human CCR5 receptor antagonists afforded orally bioavailable compounds with the ability to inhibit HIV replication in vitro.


Bioorganic & Medicinal Chemistry Letters | 2001

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.

Jeffrey J. Hale; Richard J. Budhu; Sander G. Mills; Malcolm Maccoss; Lorraine Malkowitz; Salvatore J. Siciliano; Sandra L. Gould; Julie A. DeMartino; Martin S. Springer

A series of 1,3,4-trisubstituted pyrrolidines was discovered to have the ability to displace [(125)I]-MIP-1alpha from the CCR5 receptor expressed on Chinese hamster ovary (CHO) cell membranes. CCR5 activity was found to be dependent on the regiochemistry and the absolute stereochemistry of the pyrrolidine.


Bioorganic & Medicinal Chemistry Letters | 2002

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV

Christopher L. Lynch; Jeffrey J. Hale; Richard J. Budhu; Amy Gentry; Sander G. Mills; Kevin T. Chapman; Malcolm Maccoss; Lorraine Malkowitz; Martin S. Springer; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Margaret A. Cascieri; Anthony Carella; Gwen Carver; Karen Holmes; William A. Schleif; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; Emilio A. Emini

A series of alpha-(pyrrolidin-1-yl)acetic acids is presented as selective and potent antivirals against HIV. Several of the pyrrolidine zwitterions demonstrated reasonable in vitro properties, enhanced antiviral activities and improved pharmacokinetic profiles over pyrrolidine 1.


Bioorganic & Medicinal Chemistry Letters | 2003

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains.

Christopher L. Lynch; Christopher A. Willoughby; Jeffrey J. Hale; Edward J. Holson; Richard J. Budhu; Amy Gentry; Keith G. Rosauer; Charles G. Caldwell; Ping Chen; Sander G. Mills; Malcolm Maccoss; Scott C. Berk; Liya Chen; Kevin T. Chapman; Lorraine Malkowitz; Martin S. Springer; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Margaret A. Cascieri; Anthony Carella; Gwen Carver; Karen Holmes; William A. Schleif; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; Emilio A. Emini

The 4-(3-phenylprop-1-yl)piperidine moiety of the 1,3,4-trisubstituted pyrrolidine CCR5 antagonist 1 was modified with electron deficient aromatics as well as replacement of the benzylic methylene with sulfones, gem-difluoromethylenes and alcohols in an effort to balance the antiviral potency with reasonable pharmacokinetics.


Bioorganic & Medicinal Chemistry Letters | 2003

1,3,4 trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains

Christopher A. Willoughby; Keith G. Rosauer; Jeffery Hale; Richard J. Budhu; Sander G. Mills; Kevin T. Chapman; Malcolm Maccoss; Lorraine Malkowitz; Martin S. Springer; Sandra L. Gould; Julie A. DeMartino; Salvatore J. Siciliano; Margaret A. Cascieri; Anthony Carella; Gwen Carver; Karen Holmes; William A. Schleif; Renee Danzeisen; Daria J. Hazuda; Joseph Kessler; Janet Lineberger; Michael D. Miller; Emilio A. Emini

A new class of 4-(aminoheterocycle)piperidine derived 1,3,4 trisubstituted pyrrolidine CCR5 antagonists is reported. Compound 4a is shown to have good binding affinity (1.8 nM) and antiviral activity in PBMCs (IC(95)=50 nM). Compound 4a also has improved PK properties relative to 1.


Bioorganic & Medicinal Chemistry Letters | 2002

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.

Jeffrey J. Hale; Richard J. Budhu; Sander G. Mills; Malcolm Maccoss; Sandra L. Gould; Julie A. DeMartino; Martin S. Springer; Salvatore J. Siciliano; Lorraine Malkowitz; William A. Schleif; Daria J. Hazuda; Michael D. Miller; Joseph Kessler; Renee Danzeisen; Karen Holmes; Janet Lineberger; Anthony Carella; Gwen Carver; Emilio A. Emini

Incorporation of acidic functional groups into a lead CCR5 antagonist identified from a targeted combinatorial library resulted in compounds with enhanced anti-HIV-1 activity and attenuated L-type calcium channel affinity.


Bioorganic & Medicinal Chemistry Letters | 1993

1,4-diacylpiperazine-2-(S)-[(N-aminoalkyl)carboxamides] as novel, potent substance P receptor antagonists

Sander G. Mills; Mu Tsu Wu; Malcolm Maccoss; Richard J. Budhu; Conrad P. Dorn; Margaret A. Cascieri; Sharon Sadowski; Catherine D. Strader; William J. Greenlee

Abstract A series of N,N′-diacylpiperazine-2-carboxamides are shown to be antagonists of the NK-1 (Substance P) receptor. Elaboration of the C2 sidechain with aminoalkyl groups leads to two series of potent antagonists, one containing simple dialkylamino groups and the second featuring 2-methoxybenzylamino derivatives with divergent SARs with respect to substitution at the C2 amide bond.


Bioorganic & Medicinal Chemistry Letters | 1995

1,2,3-Trisubstituted cyclohexyl substance P antagonists: Significance of the ring nitrogen in piperidine-based NK-1 receptor antagonists

Sander G. Mills; Malcolm Maccoss; Dennis J. Underwood; Shrenik K. Shah; Paul E. Finke; Daniel J. Miller; Richard J. Budhu; Margaret A. Cascieri; Sharon Sadowski; Catherine D. Strader

Abstract A stereocontrolled synthesis of 1-benzyloxy-2-phenylcyclohexane derivatives containing polar substituents at C3 is described. These compounds, designed to test the role of the ring nitrogen in a related series of potent piperidine-based substance P antagonists, show similar NK-1 receptor affinity, indicating that the nitrogen may serve a largely structural role in N-substituted piperidine antagonists.


Archive | 1998

Pyrrolidine and piperidine modulators of chemokine receptor activity

Richard J. Budhu; Edward Holson; Jeffrey J. Hale; Christopher L. Lynch; Malcolm Maccoss; Scott C. Berk; Sander G. Mills; Christopher A. Willoughby

Collaboration


Dive into the Richard J. Budhu's collaboration.

Researchain Logo
Decentralizing Knowledge